Skip to main content
Top
Published in: Medical Oncology 7/2014

01-07-2014 | Original Paper

Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review

Authors: Jian Zhang, Linlin Ma, Zelin Xie, Yuwen Guo, Wen Sun, Lei Zhang, Jun Lin, Jing Xiao, Yichen Zhu, Ye Tian

Published in: Medical Oncology | Issue 7/2014

Login to get access

Abstract

This study investigated the incidence and types of post-transplant malignancy in Chinese renal transplant recipients and the risk factors associated with malignancy. Data from 3,462 patients who underwent renal transplantation at Beijing Friendship Hospital were combined with data from 26 previous reports describing malignancy rates in 27,170 Chinese renal transplant recipients. Between 1974 and 2014, 179/3,462 (5.17 %) patients who underwent renal transplantation at our center developed malignancy. The most common site of malignancy was the urinary system, and the most common type was urothelial transitional cell carcinoma. Combined data from our center and previous reports showed malignancy in 671 (2.19 %) Chinese renal transplant recipients. The ten most common malignancies were urothelial transitional cell carcinoma (n = 283), hepatocellular carcinoma (n = 68), gastrointestinal cancer (n = 63), renal cell carcinoma (n = 42), lymphoma (n = 42), lung cancer (n = 28), breast cancer (n = 19), skin cancer (n = 18), Kaposi’s sarcoma (n = 12), and cervical cancer (n = 10). The incidence of post-transplant malignancy in renal transplant recipients was lower in China than the reported rates in other countries, and the most common sites of malignancy were the urinary and digestive system. The relative frequency of malignancy sites differed between northern and southern China. Renal transplant recipients on long-term immunosuppressive therapy should receive careful follow-up, including annual or biannual screening for malignancy in high-risk individuals.
Literature
1.
go back to reference Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227–43.PubMedCrossRef Marcén R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009;69(16):2227–43.PubMedCrossRef
2.
go back to reference Navarro MD, López-Andréu M, Rodríguez-Benot A, Agüera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008;40(9):2936–40.PubMedCrossRef Navarro MD, López-Andréu M, Rodríguez-Benot A, Agüera ML, Del Castillo D, Aljama P. Cancer incidence and survival in kidney transplant patients. Transplant Proc. 2008;40(9):2936–40.PubMedCrossRef
3.
go back to reference Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16(2):14–8.PubMed Watorek E, Boratynska M, Smolska D, Patrzalek D, Klinger M. Malignancy after renal transplantation in the new era of immunosuppression. Ann Transplant. 2011;16(2):14–8.PubMed
4.
go back to reference Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2013. doi:10.1038/ki.2013.458.PubMed Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, Sharif A. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2013. doi:10.​1038/​ki.​2013.​458.PubMed
5.
go back to reference Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG. Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31(3):288–91 (in Chinese).PubMed Liu GH, Li HZ, Wang HJ, Mao QZ, Xia M, Xie Y, Xue C, Wang H, Ji ZG. Occurrence, types, and therapies of malignant tumors in recipients of renal transplantation. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31(3):288–91 (in Chinese).PubMed
6.
go back to reference Cao WJ, Liu ZZ, Li JX. Clinical analysis of malignant tumors after kidney transplantation. Chin Mod Med. 2012;19(2):22–4 (in Chinese). Cao WJ, Liu ZZ, Li JX. Clinical analysis of malignant tumors after kidney transplantation. Chin Mod Med. 2012;19(2):22–4 (in Chinese).
7.
go back to reference Fan Y, Tan MY. Clinical experience in treatment of malignant tumors after kidney transplantation. Chin J Org Transplant. 2009;30(1):34–6 (in Chinese). Fan Y, Tan MY. Clinical experience in treatment of malignant tumors after kidney transplantation. Chin J Org Transplant. 2009;30(1):34–6 (in Chinese).
8.
go back to reference Xu ZQ, Xu HY. Malignancy after renal transplantation: report of 4 cases. J Clin Urol. 2002;17(1):46 (in Chinese). Xu ZQ, Xu HY. Malignancy after renal transplantation: report of 4 cases. J Clin Urol. 2002;17(1):46 (in Chinese).
9.
go back to reference Long W, Yang GT, Jiang W, Liu YB, Pei XK, Bai YM. Sixteen cases of malignant tumor after renal transplantation: clinical report and literature review. Chin J Tissue Eng Res. 2012;16(40):7450–4 (in Chinese). Long W, Yang GT, Jiang W, Liu YB, Pei XK, Bai YM. Sixteen cases of malignant tumor after renal transplantation: clinical report and literature review. Chin J Tissue Eng Res. 2012;16(40):7450–4 (in Chinese).
10.
go back to reference Chen GY, Yao XP, Chen YY, Jiang JG. Clinical study of malignancy in renal allograft recipients. J Clin Urol. 2003;18(3):144–5 (in Chinese). Chen GY, Yao XP, Chen YY, Jiang JG. Clinical study of malignancy in renal allograft recipients. J Clin Urol. 2003;18(3):144–5 (in Chinese).
11.
go back to reference Xu XM, Zhang Y, Xu ZQ, Zheng SL, Yang YR, Xia P. Profiles of malignant tumors following kidney transplantation: an analysis of 34 cases. Chin J Transplant (Electronic Edition). 2012;6(2):97–104 (in Chinese). Xu XM, Zhang Y, Xu ZQ, Zheng SL, Yang YR, Xia P. Profiles of malignant tumors following kidney transplantation: an analysis of 34 cases. Chin J Transplant (Electronic Edition). 2012;6(2):97–104 (in Chinese).
12.
go back to reference Hu XP, Ma LL, Zhang XD, Chen X, Wang W, Li XB, Wang Y. Clinical analysis of malignant tumor following renal transplantation. J Clin Surg. 2006;14(8):504–5 (in Chinese). Hu XP, Ma LL, Zhang XD, Chen X, Wang W, Li XB, Wang Y. Clinical analysis of malignant tumor following renal transplantation. J Clin Surg. 2006;14(8):504–5 (in Chinese).
13.
go back to reference Niu B, Lin J, Chen XY, Li YC. Clinical analysis of de novo malignancies after renal transplantation. Org Transplant. 2013;4(2):91–4 (in Chinese). Niu B, Lin J, Chen XY, Li YC. Clinical analysis of de novo malignancies after renal transplantation. Org Transplant. 2013;4(2):91–4 (in Chinese).
14.
go back to reference Hao JW, Song H, Chang Z, Lin CS, Zhang AM, Li XT. Clinical study of 39 patients with malignant tumor after renal transplantation. Cancer Res Clin. 2012;24(1):38–40 (in Chinese). Hao JW, Song H, Chang Z, Lin CS, Zhang AM, Li XT. Clinical study of 39 patients with malignant tumor after renal transplantation. Cancer Res Clin. 2012;24(1):38–40 (in Chinese).
15.
go back to reference Zheng QY, Yang L, Hua X, Luo YB. Clinical analysis of malignant tumor after renal transplantation. J Pract Med. 2010;26(13):2365–7 (in Chinese). Zheng QY, Yang L, Hua X, Luo YB. Clinical analysis of malignant tumor after renal transplantation. J Pract Med. 2010;26(13):2365–7 (in Chinese).
16.
go back to reference Ma P, Sun XQ, Chen JC, Wen RM. Malignancy after renal transplantation: report of 3 cases. Acta Acad Med Xuzhou. 2003;23(1):77–8 (in Chinese). Ma P, Sun XQ, Chen JC, Wen RM. Malignancy after renal transplantation: report of 3 cases. Acta Acad Med Xuzhou. 2003;23(1):77–8 (in Chinese).
17.
go back to reference Yu LX, Miao Y, Deng WF, Du YJ, Yu J, Fu SJ, Xu J, Du CF, Wang YB, Ye GR, Hu P. De novo cancers in kidney transplant recipients. Chin J Org Transplant. 2010;31(5):265–8 (in Chinese). Yu LX, Miao Y, Deng WF, Du YJ, Yu J, Fu SJ, Xu J, Du CF, Wang YB, Ye GR, Hu P. De novo cancers in kidney transplant recipients. Chin J Org Transplant. 2010;31(5):265–8 (in Chinese).
18.
go back to reference Fan Y, Shi BY, Chang JY, Bo HW, Wang Z, Ou YY, Du Y, Qian YY. Analysis on the occurrence of malignant tumors after kidney transplantation. Med J Chin PLA. 2007;32(5):529–30 (in Chinese). Fan Y, Shi BY, Chang JY, Bo HW, Wang Z, Ou YY, Du Y, Qian YY. Analysis on the occurrence of malignant tumors after kidney transplantation. Med J Chin PLA. 2007;32(5):529–30 (in Chinese).
19.
go back to reference Lin Z, Zhang JF, Chen J, Shao YQ, Zhang YB, Tong L, Hu ZX, Dong SF. Malignancy following renal transplantation: an analysis of 6 cases. Chin J Org Transplant. 2004;25(4):250 (in Chinese). Lin Z, Zhang JF, Chen J, Shao YQ, Zhang YB, Tong L, Hu ZX, Dong SF. Malignancy following renal transplantation: an analysis of 6 cases. Chin J Org Transplant. 2004;25(4):250 (in Chinese).
20.
go back to reference Dong J, Ao JH, Xiao XR, Ye LY, Hong BF, Wang XX, Li YT. Malignancies following renal transplantation: A report of 19 cases. Chin J Org Transplant. 2001;22(4):214–5 (in Chinese). Dong J, Ao JH, Xiao XR, Ye LY, Hong BF, Wang XX, Li YT. Malignancies following renal transplantation: A report of 19 cases. Chin J Org Transplant. 2001;22(4):214–5 (in Chinese).
21.
go back to reference Zhao XH, Guo QX, Qin F. Clinical analysis of 14 patients with malignancy after renal transplantation. J Zhengzhou Univ (Medical Sciences). 2004;39(4):731 (in Chinese). Zhao XH, Guo QX, Qin F. Clinical analysis of 14 patients with malignancy after renal transplantation. J Zhengzhou Univ (Medical Sciences). 2004;39(4):731 (in Chinese).
22.
go back to reference Qu LH, Li Q, Chen JH, Wu JY, Wang YM, Zhang JG, Wang SY, Huang HF, He Q. Clinical analysis of malignant tumors in recipients of renal transplantation. Chin J Urol. 2004;25(7):445–7 (in Chinese). Qu LH, Li Q, Chen JH, Wu JY, Wang YM, Zhang JG, Wang SY, Huang HF, He Q. Clinical analysis of malignant tumors in recipients of renal transplantation. Chin J Urol. 2004;25(7):445–7 (in Chinese).
23.
go back to reference Yang HW, Xiang J, Liu L, Wu QS, Duan WL. Malignancy following renal transplantation: report of 17 cases. Shenyang Bu Dui Yi Yao. 2003;16(6):527 (in Chinese). Yang HW, Xiang J, Liu L, Wu QS, Duan WL. Malignancy following renal transplantation: report of 17 cases. Shenyang Bu Dui Yi Yao. 2003;16(6):527 (in Chinese).
24.
go back to reference Tian XJ, Ma LL, Wang GL, Hou XF, Luo KP, Zhao L. Malignancies in renal transplant recipients: a report of 6 cases. J Clin Urol. 2005;20(1):49–50 (in Chinese). Tian XJ, Ma LL, Wang GL, Hou XF, Luo KP, Zhao L. Malignancies in renal transplant recipients: a report of 6 cases. J Clin Urol. 2005;20(1):49–50 (in Chinese).
25.
go back to reference Lin RX, Yang SL, Wu WZ, Lin WH. Malignant tumor following renal transplantation. Chin J Org Transplant. 2003;24(3):139–40 (in Chinese). Lin RX, Yang SL, Wu WZ, Lin WH. Malignant tumor following renal transplantation. Chin J Org Transplant. 2003;24(3):139–40 (in Chinese).
26.
go back to reference Fei JG, Chen LZ, Zhao JQ, Wang CX, Qiu J, Deng SX, Li J, Chen GD. Analysis on the risk factors and prognosis of malignant tumor in kidney transplantation recipients. Chin J Org Transplant. 2008;29(10):617–9 (in Chinese). Fei JG, Chen LZ, Zhao JQ, Wang CX, Qiu J, Deng SX, Li J, Chen GD. Analysis on the risk factors and prognosis of malignant tumor in kidney transplantation recipients. Chin J Org Transplant. 2008;29(10):617–9 (in Chinese).
27.
go back to reference Dong CB, Zhu YH, Zhou MS, Wang YW, Min ZL. Analysis of malignant tumor following renal transplantation. J Clin Urol. 2004;19(2):67–8 (in Chinese). Dong CB, Zhu YH, Zhou MS, Wang YW, Min ZL. Analysis of malignant tumor following renal transplantation. J Clin Urol. 2004;19(2):67–8 (in Chinese).
28.
go back to reference Yu X, Xu DL, Bo JM, Liu M, Lu P, Lv Q, Zhang W, Gu M. Clinical analysis of 15 patients with malignancy following renal transplantation. Acta Univ Med Nanjing (Nat Sci). 2010;30(9):1330–2 (in Chinese). Yu X, Xu DL, Bo JM, Liu M, Lu P, Lv Q, Zhang W, Gu M. Clinical analysis of 15 patients with malignancy following renal transplantation. Acta Univ Med Nanjing (Nat Sci). 2010;30(9):1330–2 (in Chinese).
29.
go back to reference Wang HM, Gao CJ. Clinical analysis of malignancy in renal transplant recipients. Chin J Coal Indus Med. 2005;8(1):71–2 (in Chinese). Wang HM, Gao CJ. Clinical analysis of malignancy in renal transplant recipients. Chin J Coal Indus Med. 2005;8(1):71–2 (in Chinese).
30.
go back to reference Xu RF, He XZ, Chao ZF, Che WJ, Jing H. Malignancy after renal transplantation: report of 6 cases. J Mod Urol. 2004;9(1):45–6. Xu RF, He XZ, Chao ZF, Che WJ, Jing H. Malignancy after renal transplantation: report of 6 cases. J Mod Urol. 2004;9(1):45–6.
32.
go back to reference Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):523–8.PubMedCrossRef Vasudev B, Hariharan S. Cancer after renal transplantation. Curr Opin Nephrol Hypertens. 2007;16(6):523–8.PubMedCrossRef
33.
go back to reference Haberal AN, Süren D, Demirhan B, Bilezikçi B, Celasun B, Haberal M. Evaluation of post transplantation malignancies compared with de novo tumors. Transplant Proc. 2007;39(4):1057–62.PubMedCrossRef Haberal AN, Süren D, Demirhan B, Bilezikçi B, Celasun B, Haberal M. Evaluation of post transplantation malignancies compared with de novo tumors. Transplant Proc. 2007;39(4):1057–62.PubMedCrossRef
34.
go back to reference Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc. 2006;38(4):1135–7.PubMedCrossRef Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Transplant Proc. 2006;38(4):1135–7.PubMedCrossRef
35.
go back to reference Sheil AG, Disney AP, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc. 1992;24(5):1946–7.PubMed Sheil AG, Disney AP, Mathew TG, Amiss N, Excell L. Malignancy following renal transplantation. Transplant Proc. 1992;24(5):1946–7.PubMed
36.
go back to reference Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7(2):147–56.PubMed Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7(2):147–56.PubMed
37.
go back to reference Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, He J. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.PubMedCentralPubMed Chen WQ, Zheng RS, Zhang SW, Zhao P, Zeng HM, Zou XN, He J. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014;26(1):48–58.PubMedCentralPubMed
38.
go back to reference Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905–13.PubMedCrossRef
39.
go back to reference Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, Tóth A, Perner F, Járay J. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007;13(1):63–9.PubMedCrossRef Végso G, Tóth M, Hídvégi M, Toronyi E, Langer RM, Dinya E, Tóth A, Perner F, Járay J. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007;13(1):63–9.PubMedCrossRef
40.
go back to reference Stratta P, Morellini V, Musetti C, Turello E, Palmieri D, Lazzarich E, Cena T, Magnani C. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transplant. 2008;22(4):424–7.PubMedCrossRef Stratta P, Morellini V, Musetti C, Turello E, Palmieri D, Lazzarich E, Cena T, Magnani C. Malignancy after kidney transplantation: results of 400 patients from a single center. Clin Transplant. 2008;22(4):424–7.PubMedCrossRef
41.
go back to reference Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.PubMedCentralPubMedCrossRef Adami J, Gäbel H, Lindelöf B, Ekström K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89(7):1221–7.PubMedCentralPubMedCrossRef
42.
go back to reference Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transplant Int. 2000;13(suppl 1):S394–8.CrossRef Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transplant Int. 2000;13(suppl 1):S394–8.CrossRef
43.
go back to reference Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8.PubMedCrossRef Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941–8.PubMedCrossRef
44.
go back to reference Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, Chapman JR, Webster AC, Kaldor JM, Grulich AE. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–31.PubMedCrossRef
45.
go back to reference Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, Aozasa K. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.PubMedCrossRef Hoshida Y, Tsukuma H, Yasunaga Y, Xu N, Fujita MQ, Satoh T, Ichikawa Y, Kurihara K, Imanishi M, Matsuno T, Aozasa K. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71(4):517–20.PubMedCrossRef
46.
go back to reference Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, Joh JW. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc. 2013;45(8):3019–23.PubMedCrossRef Shin M, Moon HH, Kim JM, Park JB, Kwon CH, Kim SJ, Joh JW. Comparison of the incidence of de novo malignancy in liver or kidney transplant recipients: analysis of 2673 consecutive cases in a single center. Transplant Proc. 2013;45(8):3019–23.PubMedCrossRef
47.
go back to reference Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–86.PubMedCentralPubMedCrossRef Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst. 2010;102(3):179–86.PubMedCentralPubMedCrossRef
48.
go back to reference Zhou L, Cao YL, Li WG, Fu FT, Zhang L, Wang X, Shi XH. Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China. Chin Med J (Engl). 2012;125(24):4460–5. Zhou L, Cao YL, Li WG, Fu FT, Zhang L, Wang X, Shi XH. Transitional cell carcinoma associated with aristolochic acid nephropathy: most common cancer in chronic hemodialysis patients in China. Chin Med J (Engl). 2012;125(24):4460–5.
49.
go back to reference Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.PubMedCrossRef Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.PubMedCrossRef
50.
go back to reference Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.PubMedCentralPubMedCrossRef Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk factors for hepatocellular carcinoma after solid organ transplantation. Transplantation. 2008;86(6):784–90.PubMedCentralPubMedCrossRef
51.
go back to reference Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong renal registry. Ren Fail. 2014. doi:10.3109/0886022X.2014.899879.PubMed Cheung CY, Lam MF, Chow KM, Lee W, Cheng YL, Yuen SK, Wong PN, Mo KL, Leung KT, Wong SH, Ho YW, Chau KF. Hepatocellular carcinoma after kidney transplantation: analysis of Hong Kong renal registry. Ren Fail. 2014. doi:10.​3109/​0886022X.​2014.​899879.PubMed
52.
go back to reference Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96(7):1127–34.PubMedCentralPubMedCrossRef Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer. 2007;96(7):1127–34.PubMedCentralPubMedCrossRef
53.
go back to reference Huang ZJ, Zhou MG, Wang LJ. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China (Article in Chinese). Dis Surv. 2007;22(4):242–5. Huang ZJ, Zhou MG, Wang LJ. Study on the geographic distribution of liver cancer mortality and HBsAg carrier rate in China (Article in Chinese). Dis Surv. 2007;22(4):242–5.
54.
go back to reference Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujiil T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014. doi:10.1111/bju.12707.PubMed Ishioka J, Saito K, Kijima T, Nakanishi Y, Yoshida S, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Sakai Y, Arisawa C, Okuno T, Nagahama K, Kamata S, Sakura M, Yonese J, Morimoto S, Noro A, Tsujiil T, Kitahara S, Gotoh S, Higashi Y, Kihara K. Risk stratification for bladder recurrence of upper urinary tract urothelial carcinoma after radical nephroureterectomy. BJU Int. 2014. doi:10.​1111/​bju.​12707.PubMed
55.
go back to reference Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53(8):943–9.PubMedCrossRef Kim B, Choi HJ, Kim MH, Cho KS. Recurrence patterns of bladder transitional cell carcinoma after radical cystectomy. Acta Radiol. 2012;53(8):943–9.PubMedCrossRef
Metadata
Title
Epidemiology of post-transplant malignancy in Chinese renal transplant recipients: a single-center experience and literature review
Authors
Jian Zhang
Linlin Ma
Zelin Xie
Yuwen Guo
Wen Sun
Lei Zhang
Jun Lin
Jing Xiao
Yichen Zhu
Ye Tian
Publication date
01-07-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 7/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0032-6

Other articles of this Issue 7/2014

Medical Oncology 7/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.